GSK Spins Out Pain Assets Into Convergence

The first spin-out company to result from GlaxoSmith-Kline PLC’s exit from key CNS areas including pain and depression was announced on October 4. UK-based Convergence Pharmaceuticals Ltd. raised $35.4 million (£22.4 million) in one of Europe’s largest Series A rounds.